ArticleInternational journal of clinical oncology2025
Trends in the use of Japanese herbal Kampo medicine in inpatients with cancer: a 14-year nationwide analysis.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Nationwide Practice Patterns of Early Postoperative Kampo Medicine after Gastrectomy for Gastric Cancer: A Japanese Administrative Database Study.Journal of gastrointestinal cancer · 2026Article
- Efficacy of Phytotherapy for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Diseases (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundKampo medicine (Japanese herbal medicine) is often used to manage the side effects of cancer treatment and improve quality of life. However, nationwide trends in Kampo use among inpatients with cancer in Japan remain poorly understood. This study aimed to examine the temporal trends and clinical practice patterns of Kampo prescriptions among inpatients with cancer between 2010 and 2023, with a focus on their use in acute or severe conditions.
methodsThis retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including over 6.8 million hospitalizations for five major cancer types (breast, colorectal, gastric, lung, and prostate)between July 2010 and March 2023. Kampo use was identified from in-hospital prescription data. Prescription trends and patient characteristics were analyzed.
resultsKampo medicines were prescribed in 13.6% of hospitalizations, more commonly among older adults and patients with colorectal cancer. The overall prescription proportion increased from 2010 to 2017 before plateauing. The top five prescribed Kampo medicines were Dai-ken-chu-to, Gosha-jinki-gan, Rikkunshi-to, Shakuyaku-kanzo-to, and Hange-shashin-to. Prescription patterns varied by age group, cancer type, cancer stage, disease status, and cause of hospitalization. Dai-ken-chu-to use shifted from postoperative to chronic care, while Gosha-jinki-gan prescriptions gradually declined.
conclusionsKampo prescription patterns among inpatients with cancer have changed over the past fourteen years, reflecting changes in patient demographics and treatment strategies. Kampo medicines appear to be selectively used as supportive care tailored to specific clinical situations. These findings highlight the evolving role of traditional medicine in modern cancer care in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.